315 related articles for article (PubMed ID: 22516679)
1. Structural elucidation of impurities in 5-n-butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichlorophenyl)-3H-1,2,4-triazol-3-one (Ib), a novel nonpeptide angiotensin AT1 receptor antagonist.
Gao T; Liu Y; Ji Y; Wu X; Xu J
J Pharm Biomed Anal; 2012 Jul; 66():381-6. PubMed ID: 22516679
[TBL] [Abstract][Full Text] [Related]
2. Identification of the major metabolites of 5-n-butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichloridephenyl)-3H-1,2,4-triazol-3-one, a new angiotensin type 1 receptor antagonist, in rat bile by HPLC-diode array detection-MS and HPLC-MS/MS.
Yan B; Wang G; Sun J; Li X; Zheng Y; Ai H; Lv H; Wu X; Xu J
Biomed Chromatogr; 2007 Sep; 21(9):912-24. PubMed ID: 17428010
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of potential impurities of valsartan, AT1 receptor antagonist.
Sampath A; Reddy AR; Yakambaram B; Thirupathi A; Prabhakar M; Reddy PP; Reddy VP
J Pharm Biomed Anal; 2009 Oct; 50(3):405-12. PubMed ID: 19560892
[TBL] [Abstract][Full Text] [Related]
4. Atypical Kinetics and Albumin Effect of Glucuronidation of 5-n-Butyl-4-{4-[2-(1H-tetrazole-5- yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6- dichlorophenyl)-3H-1,2,4-triazol-3-one, a Novel Nonpeptide Angiotensin Type 1 Receptor Antagonist, in Liver Microsomes and UDP-Glucuronosyl-transferase.
Peng Y; Zhang X; Zhu Y; Wu H; Gu S; Chang Q; Zhou Y; Wang G; Sun J
Molecules; 2018 Mar; 23(3):. PubMed ID: 29562678
[TBL] [Abstract][Full Text] [Related]
5. Identification, isolation and characterization of process-related impurities in Rizatriptan benzoate.
Raj TJ; Bharathi Ch; Kumar MS; Prabahar J; Kumar PN; Sharma HK; Parikh K
J Pharm Biomed Anal; 2009 Jan; 49(1):156-62. PubMed ID: 19056198
[TBL] [Abstract][Full Text] [Related]
6. Characterization of angiotensin II antagonism displayed by Ib, a novel nonpeptide angiotensin AT(1) receptor antagonist.
Wu J; Wang Q; Guo J; Hu Z; Yin Z; Xu J; Wu X
Eur J Pharmacol; 2008 Jul; 589(1-3):220-4. PubMed ID: 18571160
[TBL] [Abstract][Full Text] [Related]
7. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS.
Thomas S; Bharti A; Maddhesia PK; Shandilya S; Agarwal A; Dharamvir ; Biswas S; Bhansal V; Gupta AK; Tewari PK; Mathela CS
J Pharm Biomed Anal; 2012 Mar; 61():165-75. PubMed ID: 22178334
[TBL] [Abstract][Full Text] [Related]
8. Investigation and structural elucidation of a process related impurity in candesartan cilexetil by LC/ESI-ITMS and NMR.
Raman B; Sharma BA; Mahale G; Singh D; Kumar A
J Pharm Biomed Anal; 2011 Sep; 56(2):256-63. PubMed ID: 21664089
[TBL] [Abstract][Full Text] [Related]
9. Critical practical aspects in the application of liquid chromatography-mass spectrometric studies for the characterization of impurities and degradation products.
Narayanam M; Handa T; Sharma P; Jhajra S; Muthe PK; Dappili PK; Shah RP; Singh S
J Pharm Biomed Anal; 2014 Jan; 87():191-217. PubMed ID: 23706957
[TBL] [Abstract][Full Text] [Related]
10. Characterization of two new potential impurities of Valsartan obtained under photodegradation stress condition.
Bianchini RM; Castellano PM; Kaufman TS
J Pharm Biomed Anal; 2011 Aug; 56(1):16-22. PubMed ID: 21592713
[TBL] [Abstract][Full Text] [Related]
11. Four process-related potential new impurities in ticagrelor: Identification, isolation, characterization using HPLC, LC/ESI-MS(n), NMR and their synthesis.
Kumar N; Devineni SR; Gajjala PR; Gupta DK; Bhat S; Kumar R; Dubey SK; Kumar P
J Pharm Biomed Anal; 2016 Feb; 120():248-60. PubMed ID: 26760243
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of some new 1,3,4-thiadiazol-2-ylmethyl-1,2,4-triazole derivatives and investigation of their antimicrobial activities.
Demirbas A; Sahin D; Demirbas N; Karaoglu SA
Eur J Med Chem; 2009 Jul; 44(7):2896-903. PubMed ID: 19167136
[TBL] [Abstract][Full Text] [Related]
13. Investigation of amodiaquine bulk drug impurities by liquid chromatography/ion trap mass spectrometry.
Dongre VG; Karmuse PP; Ghugare PD; Kanojiya SK; Rawal S
Rapid Commun Mass Spectrom; 2008 Jul; 22(14):2227-33. PubMed ID: 18543378
[TBL] [Abstract][Full Text] [Related]
14. Isolation and structure elucidation of unexpected in-process impurities during tetrazole ring formation of an investigational drug substance.
Silva Elipe MV; Yoo C; Xia F; Simiens J; Crossley K; Huckins JR; Guo HX; Tedrow J; Wong-Moon K
Magn Reson Chem; 2017 Apr; 55(4):253-262. PubMed ID: 26841697
[TBL] [Abstract][Full Text] [Related]
15. Isolation and structural identification of an impurity in fluconazole bulk drug substance.
Dongre VG; Ghugare PD; Karmuse PP; Soudagar SR; Panda N; Kumar A
J Pharm Biomed Anal; 2007 Nov; 45(3):422-9. PubMed ID: 17706390
[TBL] [Abstract][Full Text] [Related]
16. Potential impurities of anxiolytic drug, clobazam: Identification, synthesis and characterization using HPLC, LC-ESI/MS
Kumar N; Devineni SR; Dubey SK; Kumar P
J Pharm Biomed Anal; 2017 Apr; 137():268-278. PubMed ID: 28183048
[TBL] [Abstract][Full Text] [Related]
17. Isolation, synthesis and characterization of impurities in celecoxib, a COX-2 inhibitor.
Satyanarayana U; Rao DS; Kumar YR; Babu JM; Kumar PR; Reddy JT
J Pharm Biomed Anal; 2004 Jun; 35(4):951-7. PubMed ID: 15193741
[TBL] [Abstract][Full Text] [Related]
18. Preparative isolation and structural elucidation of impurities in fluconazole by LC/MS/MS.
Dongre VG; Karmuse PP; Ghugre PD; Salunke SM; Panda N; Kumar A
J Pharm Biomed Anal; 2006 Sep; 42(3):334-40. PubMed ID: 16757140
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist?
Dams I; Ostaszewska A; Puchalska M; Chmiel J; Cmoch P; Bujak I; Białońska A; Szczepek WJ
Molecules; 2015 Dec; 20(12):21346-63. PubMed ID: 26633332
[TBL] [Abstract][Full Text] [Related]
20. Structural identification and characterization of impurities in moxifloxacin.
Kumar YR; Prasad Raju VV; Kumar RR; Eswaraiah S; Mukkanti K; Suryanarayana MV; Reddy MS
J Pharm Biomed Anal; 2004 Mar; 34(5):1125-9. PubMed ID: 15019047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
